Cargando…

Real Life Data on OnabotulinumtoxinA for Treatment of Chronic Migraine in Pediatric Age

Background: The use of OnabotulinumtoxinA (OBT-A) for the treatment of chronic migraine (CM) in adults represents a therapy with the greatest efficacy and safety data. However, we have little evidence on the use of OBT-A in children or adolescents. The present study aims to describe the experience w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Papetti, Laura, Frattale, Ilaria, Ursitti, Fabiana, Sforza, Giorgia, Monte, Gabriele, Ferilli, Michela Ada Noris, Tarantino, Samuela, Proietti Checchi, Martina, Valeriani, Massimiliano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10003637/ https://www.ncbi.nlm.nih.gov/pubmed/36902596 http://dx.doi.org/10.3390/jcm12051802

Ejemplares similares

Long-Term Effects of COVID-19 Pandemic on Migraine in Adolescents. A Retrospective Analysis of the Population Attending the Headache Center in Different Phases of the Pandemic
por: Checchi, Martina Proietti, et al.
Publicado: (2023)

Prophylactic Treatment of Pediatric Migraine: Is There Anything New in the Last Decade?
por: Papetti, Laura, et al.
Publicado: (2019)

Visual Disturbances Spectrum in Pediatric Migraine
por: Frattale, Ilaria, et al.
Publicado: (2023)

Migraine and Its Equivalents: What Do They Share? A Narrative Review on Common Pathophysiological Patterns
por: Frattale, Ilaria, et al.
Publicado: (2021)

From the New Diagnostic Criteria to COVID-19 Pandemic Passing Through the Placebo Effect. What Have We Learned in the Management of Pediatric Migrane Over the Past 5 Years?
por: Papetti, Laura, et al.
Publicado: (2022)

Interictal Cognitive Performance in Children and Adolescents With Primary Headache: A Narrative Review
por: Tarantino, Samuela, et al.
Publicado: (2022)

Safety of SARS-CoV2 vaccination and COVID-19 short-term outcome in pediatric acquired demyelinating disorders of central nervous system: A single center experience
por: Monte, Gabriele, et al.
Publicado: (2023)

Sleep Disorders in Pediatric Migraine: A Questionnaire-Based Study
por: Voci, Alessandra, et al.
Publicado: (2021)

Anxiety, Depression, and Body Weight in Children and Adolescents With Migraine
por: Tarantino, Samuela, et al.
Publicado: (2020)

Tolerability of Palmitoylethanolamide in a Pediatric Population Suffering from Migraine: A Pilot Study
por: Papetti, Laura, et al.
Publicado: (2020)

Truths and Myths in Pediatric Migraine and Nutrition
por: Papetti, Laura, et al.
Publicado: (2021)

Features and Management of New Daily Persistent Headache in Developmental-Age Patients
por: Papetti, Laura, et al.
Publicado: (2021)

Pediatric Neuromyelitis Optica Spectrum Disorder: Case Series and Literature Review
por: Ferilli, Michela Ada Noris, et al.
Publicado: (2021)

Medication Overuse Withdrawal in Children and Adolescents Does Not Always Improve Headache: A Cross-Sectional Study
por: Moavero, Romina, et al.
Publicado: (2020)

Case Report: Migralepsy: The Two-Faced Janus of Neurology
por: Sforza, Giorgia, et al.
Publicado: (2021)

Neuropsychological Sequelae, Quality of Life and Adaptive Behavior in Children and Adolescents with Anti-NMDAR Encephalitis: A Narrative Review
por: Tarantino, Samuela, et al.
Publicado: (2021)

A Case Report of Pediatric Patient with Tuberous Sclerosis and Radiologically Isolated Syndrome
por: Sforza, Giorgia, et al.
Publicado: (2023)

Case report: A pediatric case of Bickerstaff brainstem encephalitis after COVID-19 vaccination and Mycoplasma pneumoniae infection: Looking for the culprit
por: Monte, Gabriele, et al.
Publicado: (2022)

Opsoclonus-Myoclonus Syndrome in Children and Adolescents: A Therapeutic Challenge
por: Auconi, Marina, et al.
Publicado: (2021)

How to Assess the Headache—Sleep Disorders Comorbidity in Children and Adolescents
por: Onofri, Agnese, et al.
Publicado: (2021)

Cognitive effects of onabotulinumtoxinA in chronic migraine
por: Ho, Susan, et al.
Publicado: (2020)

OnabotulinumtoxinA: Still the Present for Chronic Migraine
por: Baraldi, Carlo, et al.
Publicado: (2023)

Triptan efficacy does not predict onabotulinumtoxinA efficacy but improves with onabotulinumtoxinA response in chronic migraine patients
por: Eren, Ozan E., et al.
Publicado: (2020)

Clinical trials on onabotulinumtoxinA for the treatment of chronic migraine
por: Russell, Michael Bjørn
Publicado: (2011)

OnabotulinumtoxinA for chronic migraine: a critical appraisal
por: Gooriah, Rubesh, et al.
Publicado: (2015)

OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine
por: Frampton, James E., et al.
Publicado: (2018)

Prediction of patient's response to OnabotulinumtoxinA treatment for migraine
por: Parrales Bravo, Franklin, et al.
Publicado: (2019)

Adult Abdominal Migraine Improved by OnabotulinumtoxinA Injections
por: Hermanowicz, Neal
Publicado: (2021)

OnabotulinumtoxinA in chronic migraine: is the response dose dependent?
por: Zandieh, Ali, et al.
Publicado: (2022)

Safety of OnabotulinumtoxinA in the [management of] chronic migraine in pregnancy
por: Smirnoff, Liza
Publicado: (2022)

Reply: Clinical trials on onabotulinumtoxinA for the treatment of chronic migraine
por: Aurora, Sheena, et al.
Publicado: (2011)

Prolonged Effect of OnabotulinumtoxinA on Chronic Migraine in 87 Koreans
por: Byun, Jung-Ick, et al.
Publicado: (2017)

Correction to: OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine
por: Frampton, James E., et al.
Publicado: (2018)

OnabotulinumtoxinA in Chronic Migraine: A Profile of Its Use
por: Frampton, James E.
Publicado: (2020)

P045. OnabotulinumtoxinA: long term treatment for chronic migraine with medication overuse
por: Guerzoni, Simona, et al.
Publicado: (2015)

Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine
por: Diener, H-C, et al.
Publicado: (2014)

Real-World Economic Impact of OnabotulinumtoxinA in Patients With Chronic Migraine
por: Rothrock, John F, et al.
Publicado: (2014)

Treatment of Chronic Migraine with OnabotulinumtoxinA: Mode of Action, Efficacy and Safety
por: Szok, Délia, et al.
Publicado: (2015)

OnabotulinumtoxinA in the treatment of patients with chronic migraine: clinical evidence and experience
por: Chiang, Chia-Chun, et al.
Publicado: (2017)

OnabotulinumtoxinA Is an Effective Treatment for Chronic Migraine in Patients With Comorbid Fibromyalgia
por: Sastre Real, María, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hcfjoq8n9tgqb4nqs5r6lmqtq5